Back to Point72 Asset Management, L.P. Point72 Asset Management, L.P.

FDMT

11 quarters

Position history for Point72 Asset Management, L.P.Point72 Asset Management, L.P.'s holdings in 4D Molecular Therapeutics, Inc.

No. Point72 Asset Management exited its FDMT (4D Molecular Therapeutics) position in Q1 2026. Its Q4 2025 13F listed 1,539,860 shares worth $11.5M. Point72 Asset Management first reported FDMT in Q3 2022 and held it in 8 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$2.4M

Total Shares Change

-299,000

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Exited
0
-100.0%
$00.0%$9.31
0
2025-Q4
New
1.5M
-
$11.5M0.0%$7.50
39
2024-Q4
Exited
0
-100.0%
$00.0%$5.57
0
2024-Q3
New
15,341
-
$165,8400.0%$10.83
31
2024-Q1
Exited
0
-100.0%
$00.0%$31.86
0
2023-Q4
Decreased
416,020
-8.2%
$8.4M0.0%$20.26
0
2023-Q3
Increased
453,376
+22.2%
$5.8M0.0%$12.73
33
2023-Q2
Increased
370,887
+77.5%
$6.7M0.0%$17.73
41
2023-Q1
Increased
208,900
+50.0%
$3.6M0.0%$16.75
37
2022-Q4
Decreased
139,300
-53.4%
$3.1M0.0%$22.21
0
2022-Q3
New
299,000
-
$2.4M0.0%$8.22
36

Other major holders of FDMT: Viking Global Investors LP, RA Capital Management, L.P., BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used